Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer - PubMed
6 hours ago
- #immunotherapy
- #non-small cell lung cancer
- #gut microbiota
- Low-dose intestinal irradiation (ILDR) enhances PD-1 blockade efficacy in metastatic non-small cell lung cancer (mNSCLC).
- Optimal efficacy observed with small intestinal mean radiation dose (SIMRD) of 1-3 Gy, leading to longer progression-free survival (PFS) and overall survival (OS).
- Higher (>3 Gy) or lower (<1 Gy) SIMRD independently predicted worse OS.
- Prospective results confirmed best disease control rate and PFS with SIMRD of 1-3 Gy.
- Responders showed enrichment in Bacillota, Clostridia, and indole derivatives like indole-3-carboxylic acid.
- 1-3 Gy group exhibited increased macrophage inflammatory protein-3α and reduced α4β7+ regulatory T cells.
- ILDR likely modulates the gut microbiota-metabolite-immune axis to enhance PD-1 blockade efficacy.